Itraconazole: Difference between revisions
(Text replacement - "*CHF" to "*CHF") |
(Text replacement - "*Pancreatitis" to "*Pancreatitis") |
||
| Line 29: | Line 29: | ||
*Hepatotoxicity | *Hepatotoxicity | ||
*SJS/TEN | *SJS/TEN | ||
*Pancreatitis | *[[Pancreatitis]] | ||
===Common=== | ===Common=== | ||
*Nausea/vomiting, diarrhea, abdominal pain | *Nausea/vomiting, diarrhea, abdominal pain | ||
Revision as of 21:09, 25 September 2016
Administration
- Type: Antifungal
- Dosage Forms: Capsule, solution (for oropharyngeal/esophageal candida)
- Routes of Administration:
- Common Trade Names:
Adult Dosing
- 200mg PO 1-4 times per day
Pediatric Dosing
- > 5y: 2.5-10mg/kg 2-3 times per day
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
Renal Dosing
- Adult: No adjustment
- Pediatric:
Hepatic Dosing
- Adult: No adjustment
- Pediatric:
Contraindications
- Allergy to class/drug
- Concomitant use of CYP3A4 substrates (e.g. ergots, lurasidone, methadone, oral midazolam, simvastatin, ticagrelor, and triazolam)
- Ventricular dysfunction (relative)
Adverse Reactions
Serious
- CHF, pulmonary edema
- Hepatotoxicity
- SJS/TEN
- Pancreatitis
Common
- Nausea/vomiting, diarrhea, abdominal pain
- Headache, dizziness
- Edema
- Pruritus, rash
- URI symptoms
Pharmacology
- Half-life: 32-96h
- Metabolism: Hepatic, P450 CYP3A4
- Excretion:
Mechanism of Action
- Inhibits synthesis of ergosterol (fungal cell membrane component)